Inhibitors: Resolving diagnostic and therapeutic dilemmas

Haemophilia

Volumn 8, Issue 3, 2002, Pages 280-287

  Dimichele, D ^a  

^a NEW YORK PRESBYTERIAN HOSPITAL   (United States)

Author keywords

Haemophilia A; Haemophilia B; Inhibitor therapy; Inhibitors; Neutralizing antibody

Indexed keywords

ACTIVATED PROTHROMBIN COMPLEX; BLOOD CLOTTING FACTOR 8; BLOOD CLOTTING FACTOR 8 ANTIBODY; BLOOD CLOTTING FACTOR 8 DERIVATIVE; BLOOD CLOTTING FACTOR 9; BLOOD CLOTTING INHIBITOR; DESMOPRESSIN; IMMUNOGLOBULIN G; POLYCLONAL ANTIBODY; RECOMBINANT BLOOD CLOTTING FACTOR 7A; ALLOANTIBODY;

ARTICLE; BLEEDING; CONTROLLED STUDY; DIAGNOSTIC TEST; DRUG EFFECT; DRUG EFFICACY; DRUG HALF LIFE; DRUG SAFETY; GENETIC RISK; HEMOPHILIA A; HEMOPHILIA B; HUMAN; IMMUNE RESPONSE; IMMUNOADSORPTION; IMMUNOLOGICAL TOLERANCE; INCIDENCE; PLASMAPHERESIS; PREVALENCE; PRIORITY JOURNAL; QUALITY OF LIFE; RISK FACTOR; BLOOD; GENETIC PREDISPOSITION; IMMUNOLOGY; REVIEW;

FACTOR IX; FACTOR VIII; GENETIC PREDISPOSITION TO DISEASE; HEMOPHILIA A; HEMOPHILIA B; HUMANS; ISOANTIBODIES; RISK FACTORS;

EID: 0036588771     PISSN: 13518216     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2516.2002.00626.x     Document Type: Article

References (55)

1. Ehrenforth S, Kreutz W, Scharrer I et al. Incidence of development of factor VIII and factor IX inhibitors in haemophiliacs. Lancet 1992; 339: 594-8.
2. Schwartz RS, Abildgaard CF, Aledort LM et al. Human recombinant DNA-derived antihemophilic factor (factor VIII) in the treatment of haemophilia A. N Engl J Med 1990; 323: 1800-5.
3. Bray GL, Gomperts ED, Courter S et al. A multicenter study of recombinant factor VIII (recombinate): safety, efficacy and inhibitor risk in previously untreated individuals with hemophilia A. The Recombinate Study Group Blood 1994; 83: 2428-35.
4. Lusher JM, Spira J, Rodriguez D. A four-year update of safety and efficacy of an albumin-free formulated B-domain deleted factor VIII (BBD rFVIII, rVIIISQ) in previously untreated severe hemophilia A patients. Thromb Haemost 1999; 82: 1493.
5. Ljung R, Petrini P, Tengborn L, Sjorin E. Haemophilia B mutations in Sweden: a population-based study of mutational heterogeneity. Br J Haematol 2001; 113: 81-6.
6. McMillan C, Shapiro S, Whitehurst D et al. The natural history of factor VIII. C Inhibitors in patients with hemophilia A. A national cooperative study II. Observations on the initial development of Factor VIII C inhibitors Blood 1998; 71: 344-8.
7. Gill FM. The natural history of factor VIII inhibitors in patients with hemophilia A. In: Hoyer LW, ed. Factor VIII Inhibitors. New York: Liss 1984; 19-28.
8. Addiego J, Kasper C, Abildgaard C et al. Frequency of inhibitor development in haemophiliacs treated with low-purity factor VIII. The Lancet 1993: 342: 462-4.
9. DeBiasi R, Rocino A, Papa ML et al. Incidence of factor VIII inhibitor development in hemophilia A patients treated with less pure plasma derived concentrates. Thromb Haemost 1994; 71: 544-7.
10. Kreuz W, Escuriola-Ettingshausen C, Martinez-Saguer I et al. Epidemiology of inhibitor development in haemophilia A patients treated with virus-inactivated plasma-derived clotting factor concentrates. Vox Sang 1999; 77 (Suppl. 1): 3-8.
11. Kasper CK, Aledort L, Aronson D et al. Proceedings: a more uniform measurement of factor VIII inhibitors. Thromb Diath Haemorrh 1975; 34: 612.
12. Verbruggen B, Novakova I, Wessels H et al. The Nijmegen modification of the Bethesda assay for factor VIII. C inhibitors: improved specificity and reliability. Thromb Haemost 1995; 73: 247-51.
13. Nilsson IM, Hedner U. Immunosupressive treatment in haemophiliacs with inhibitors to factor VIII and factor IX. Scand J Haematol 1976; 16: 369-82.
14. Biggs R. Antibodies to factor VIII clotting activity (VIII. C). In: Biggs R Rizza CR, eds. Human Blood Coagulation, Haemostasis and Thrombosis (3rd edn). Oxford: Blackwell Scientific Publications, 1984: 205-41.
15. White G, Rosendaal F, Aledort L et al. Recommendation of the scientific subcommittee on factor VIII and factor IX of the scientific and standardization committee of the International Society on Thrombosis and Haemostasis. Thromb Haemost 2001; 85: 560.
16. Rothschild C, Gil J, Scharrer I, Bray G. Transient inhibitors in the Recombinate PuP study. Thromb Haemost 2000; 84(1): 145-6.
17. Moreau A, Lacroix-Desmazes S, Stieltjes N et al. Antibodies to the FVIII light chain that neutralize FVIII procoagulant activity are present in plasma of nonresponder patients with severe hemophilia A and in normal polyclonal human IgG. Blood 2000; 95: 3435-41.
18. Spiegel PC, Jacquemin Jr M, Saint-Remy JMR, Stoddard BL, Pratt KP. Structure of a factor VIII C2 domain-immunoglobulin G4k Fab complex: identification of an inhibitory antibody epitope on the surface of factor VIII. Blood 2001; 98: 13-9.
19. Lacroix-Desmazes S, Sooryanarayana, Moreau A, Kazatchkine MD, Kaveri SV. Factor VIII inhibitor With catalytic activity towards factor VIII. Haematologica 2000; 85 (Suppl.): 89-92.
20. Hay CRM. Factor VIII inhibitors in mild and moderate-severity haemophilia A. Haemophilia 1998; 4: 558-63.
21. Warrier I, Ewenstein BM, Koerper M et al. Factor IX inhibitors and anaphylaxis in hemophilia B. Am J Pediatr Hematol Oncol 1997; 19: 23-7.
22. Addiego JE, JrKasper C. Abildgaard et al. Increased frequency of inhibitors in African American hemophilia A patients. Blood 1994; 1 (Suppl.): 239a.
23. Aledort LM, DiMichele DM. Inhibitor development with post-licensure use of recombinant factor VIII (rFVIII): The US hemophilia region II experience. Thromb Haemost 1997; 87A: 1997.
24. Kemball-Cook G, Tuddenham EGD, Wacey AI. The factor VIII structure and mutation resource site: hamsters, Version 4. Nucleic Acids Res 1998 26: 216-9.
25. Green P. Hemophilia B mutational database, 2001. URL: http://www.hgmd.org
26. Schwaab R, Brackmann HH, Meyer C et al. Haemophilia A. Mutation type determines risk of inhibitor formation. Thromb Haemost 1995; 74: 1402-6.
27. Astermark J, Berntorp E. Malmo International Brother Study (MIBS): An international survey of brother pairs with haemophilia. Vox Sang 1999; 77 (Suppl. 1): 80-2.
28. Hay CRM, Ollier W, Pepper L et al. HLA Class II Profile: a weak determinant of factor VIII inhibitor development in severe haemophilia A. Thromb Haemost 1997; 77: 234-7.
29. Ljung R, Petrini P, Lindgren A, Tengborn L, Nilsson I. Factor VIII and factor IX inhibitors in haemophilacs. The Lancet 1992; 339: 1550-1.
30. DiMichele D, Rothschild C, Sultan Y, Kroner B, Aledort L (members of the ISTH FVII/IX Subcommittee). Multicenter comparison of inhibitor (INH) development on plasma-derived (pd) vs. recombinant (rec) factor VIII (FVIII) in severe hemophilia A patients (sHA Pts). Blood 1999; 1 (Suppl.): 238A.
31. Scharrer I, Ehrlich HJ. Lack of evidence for increased inhibitor incidence in patients switched from plasma-derived to recombinant factor VIII. Haemophilia 2001; 7: 346-8.
32. Calvez T, Biou M, Costagliola D et al. The French haemophilia cohort: rationale and organization of a long-term national pharmacosurveillance system. Haemophilia 2001; 7 (1): 82-8.
33. Lusher JM. Controlled clinical trials with prothrombin complex concentrates. Prog Clin Biol Res 1984; 150: 277-90.
34. Leissinger CA. Use of prothrombin complex concentrates and activated prothrombin complex concentrates as prophylactic therapy in haemophilia patients with inhibitors. Haemophilia 1999; 5 (Suppl. 3): 25-32.
35. Schmidt ML, Gamerman S, Smith HE, Scot JP, DiMichele DM. Recombinant activated factor VII (rFVIIa) therapy for intracranial hemorrhage (ICH) in hemophilia A patients with inhibitors. Am J Hematol 1994; 47: 36-40.
36. Key N, Aledort LM, Beardsley D et al. Home treatment of mild to moderate bleeding episodes using recombinant factor VIIa (Novoseven) in haemophiliacs with inhibitors. Thromb Haemost 1998; 80: 912-8.
37. Shapiro A, Gilchrist G, Hoots KW, Cooper HA, Gastineau DA. Prospective, randomised trial of two doses of rFVIIa (NovoSeven) in haemophilia patients with inhibitors undergoing surgery. Thromb Haemost 1998; 80: 773-8.
38. Hay CRM. Porcine factor VIII. Past, present and future. Haematologica 2000; 85 (Suppl. 1): 21-5.
39. O'Gorman P, DiMichele DM, Kasper CK, Mannucci PM, Santagostini E, Hay CRM. Continuous infusion of porcine factor VIII in patients with haemophilia A and high responding inhibitors: stability and clinical experience. Haemophilia 2001; 7: 537-9.
40. Parker ET, Pohl J, Blackburn MN, Lollar P. Subunit structure and function of porcine factor Xa-activated factor VIII. Biochemistry 1997; 36: 9365-73.
41. Nilsson IM, Berntorp E, Zetterval O. Induction of immune tolerance in patients with hemophilia and antibodies to factor VIII by combined treatment with intravenous IgG, cyclophosphamide and factor VIII. N Engl J Med 1998; 318: 947-50.
42. Freiburghaus C, Berntorp E, Ekman M et al. Immunoadsorption for removal of inhibitors: update on treatments in Malmo-Lund between 1980 and 1995. Haemophilia 1998; 4: 16-20.
43. Santagostino E, Gringeri A, Tagliavacca L, Mannucci PM et al. Inhibitors to factor VIII in a family with mild hemophilia: molecular characterization and response to factor VIII and desmopressin. Thromb Haemost 1995; 74: 619-21.
44. Brackmann HH. Induced immunotolerance in factor VIII inhibitor patients. Prog Clin Biol Res 1984; 150: 181-95.
45. Ewing NP, Sanders NL, Dietrich SL, Kasper CK. Induction of immune tolerance to factor VIII in hemophiliacs with inhibitors. JAMA 1988; 259: 65-8.
46. Gruppo RA, Valdez LP, Stout RD. Induction of immune tolerance in patients with hemophilia A and inhibitors. Am J Pediatr Hematol Oncol 1992; 14: 82-7.
47. Mauser-Bunschoten EP, Nieuwenhuis HK, Rosendaal G, van den Berg HM. Low dose immune tolerance induction in hemophilia A patients with inhibitors. Blood 1995; 86: 983-8.
48. Mariani G, Kroner B. International Immune Tolerance Registry, 1997 Update. Vox Sang 1999; 77 (Suppl. 1): 25-7.
49. Lenk H, the, Study Group of German Haemophilia Centres. The German national immune tolerance registry, 1997 update. Vox Sang 1999; 77 (Suppl. 1): 28-30.
50. DiMichele DM, Kroner BL, the, North American Immune Tolerance Study Group. The North American immune tolerance registry. Practices, outcomes, outcome predictors. Thromb Haemost 2002; 87: 52-7.
51. DiMichele D, Kroner B. Higher immune tolerance (IT) success rate with monoclonal FVIII (mFVIII) when compared to recombinant (rFVIII): an analysis of the North American Immune Tolerance Registry (NAITR). Blood 2000; 96: 266a.
52. Nilsson IM, Berntorp E, Zetterval O. Induction of split tolerance and clinical cure in high responding hemophiliacs with factor IX antibodies. Proc Natl Acad Sci USA 1986; 83: 9169-73.
53. Warrier I. Factor IX antibody and immune tolerance. Vox Sang 1999; 77: 70-1.
54. Ewenstein BM, Takemoto C, Warrier I et al. Nephrotic syndrome as a complication of immune tolerance in hemophilia B. Blood 1997; 89: 1115-6 (Letter).
55. Pipe SW, Kaufman R. PNAS 1997; 94: 11851.